This is rather misleading.
Sirtex has annualised revenue of $160m with NPAT expected of over $36m this financial year. Lots of excess cashflow, and growing at over 20% per annum, with single digit market penetration for a product which is passed phase 3 and selling in the market for several years now.
MSB is still cashflow negative with uncertain future both on funding and on passing Phase 3.
Both are available at the same price in terms of market cap.
Take your pick.
Dolce, please do proper research on Sirtex before making comments.
This is rather misleading. Sirtex has annualised revenue of...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.010(0.90%) |
Mkt cap ! $1.270B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.10 | $5.693M | 5.093M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 114659 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 1078 | 1 |
View Market Depth
| Last trade - 14.49pm 08/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |